Malignant glioma

10 trials 8 recruiting MedDRA PT
10 Registered trials
8 Recruiting
9 Unique sponsors
14 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
L Oncology (ATC L) 5
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Vinca alkaloid 3 substances
RAF/BRAF inhibitor 1 substance
Platinum compound 1 substance
Beta-blocker 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Proteasome inhibitor 1 substance
Alkylating agent 1 substance
Phase III: 4 Phase II: 3 Phase I (Other): 2 Phase I (First in Human): 2

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase III

4 trials
  • Chimerix Inc. Commercial
    2,4,6,7,8,9-HEXAHYDRO-4-((2-METHYLPHENYL)METHYL)-7-(PHENYLMETHYL)IMIDAZO(1,2-A)PYRIDO(3,4-E)PYRIMIDIN-5(1H)-ONE
    2022-502051-56-00 6 countries 2023 n=104 Orphan
    Recruiting
  • TargED Biopharmaceuticals B.V. Commercial
    CARBOPLATIN; TOVORAFENIB; VINBLASTINE SULFATE; VINCRISTINE SULFATE
    2024-510742-13-00 16 countries 2023 n=245 Orphan
    Ended
  • Rigshospitalet Academic
    BEVACIZUMAB; LOMUSTINE
    2024-519437-27-02 1 country 2025 n=168
    Recruiting
  • Chimerix Inc. Academic
    2,4,6,7,8,9-HEXAHYDRO-4-((2-METHYLPHENYL)METHYL)-7-(PHENYLMETHYL)IMIDAZO(1,2-A)PYRIDO(3,4-E)PYRIMIDIN-5(1H)-ONE
    2022-502051-56-00 6 countries 2023 n=104 Orphan
    Recruiting

Phase II

3 trials
  • TargED Biopharmaceuticals B.V. Commercial
    TOVORAFENIB
    2024-510691-20-00 3 countries 2021 n=16 Orphan
    Recruiting
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2024-511862-35-00 1 country 2019 n=60
    Recruiting
  • Prinses Maxima Centrum voor Kinderoncologie B.V. Academic
    DORDAVIPRONE; PAXALISIB
    2023-507598-16-00 1 country 2022 n=30 Orphan
    Halted

Phase I (Other)

2 trials
  • Centre Hospitalier Regional De Marseille Academic
    PROPRANOLOL HYDROCHLORIDE; VINORELBINE TARTRATE
    2024-517185-42-00 1 country 2020 n=58
    Recruiting
  • Region Midtjylland Academic
    IMP not specified
    2025-522605-37-00 1 country 2026 n=36
    Recruiting

Phase I (First in Human)

2 trials
  • Hemerion Therapeutics Commercial
    AMINOLEVULINIC ACID HYDROCHLORIDE
    2025-520563-41-00 1 country 2025 n=6 Orphan
    Ended
  • Helse Bergen HF Academic
    BORTEZOMIB; TEMOZOLOMIDE
    2024-515142-16-00 1 country 2024 n=63
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
TargED Biopharmaceuticals B.V. Commercial 2 Phase II, Phase III 1
Chimerix Inc. Commercial 2 Phase III 2
Hemerion Therapeutics Commercial 1 Phase I (First in Human) 0
Centre Hospitalier Regional De Marseille Academic 1 Phase I (Other) 1
Region Midtjylland Academic 1 Phase I (Other) 1
Assistance Publique Hopitaux De Paris Academic 1 Phase II 1
Prinses Maxima Centrum voor Kinderoncologie B.V. Academic 1 Phase II 0
Rigshospitalet Academic 1 Phase III 1
Helse Bergen HF Academic 1 Phase I (First in Human) 1
New trials by year
2019
1
2020
1
2021
1
2022
1
2023
3
2024
1
2025
2
2026
1
← All indication landscapes